InvestorsHub Logo
Followers 4053
Posts 151257
Boards Moderated 4
Alias Born 08/05/2009

Re: powerbattles post# 657

Wednesday, 01/06/2016 4:22:24 PM

Wednesday, January 06, 2016 4:22:24 PM

Post# of 2104
The company may redesign an upcoming liver cirrhosis treatment trial to be a Phase 3 trial instead of a Phase 2 trial, the company added.

"With these latest results, we have now demonstrated emricasan's ability to cause meaningful improvements in targeted patient populations using all three measures identified by the FDA as potentially acceptable surrogate endpoints for clinical trials in patients with liver cirrhosis," CEO Steven Mento said in a statement.



CNAT